Allergan Launches See America(SM), a Bold Initiative Furthering the Fight Against Preventable Blindness

Go back to Allergan Launches See America(SM), a Bold Initiative Furthering the Fight Against Preventable Blindness

Allergen (AGN) PT Raised to $280 at Leerink Partners Following 4Q

February 9, 2017 8:07 AM EST

Leerink Partners raised its price target on Allergen (NYSE: AGN) to $280.00 (from $271.00) while maintaining a Outperform rating.

Analyst Jason Gerberry commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic... More